{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:07:56Z","timestamp":1774588076042,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.soc.2025.12.001","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T21:07:44Z","timestamp":1768424864000},"page":"191-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["T-Cell Receptor Engineered T-Cell Therapy"],"prefix":"10.1016","volume":"35","author":[{"given":"Stav","family":"Leibou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron J.","family":"Dinerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D.","family":"Klemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2025.12.001_bib2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.soc.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"10415","key":"10.1016\/j.soc.2025.12.001_bib6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.soc.2025.12.001_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.soc.2025.12.001_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soc.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"9","author":"Mittendorf","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.soc.2025.12.001_bib11","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.soc.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.12.001_bib13","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.soc.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.3390\/ijms26062620","article-title":"State of the art of immune checkpoint inhibitors in unresectable pancreatic cancer: a comprehensive systematic review","volume":"26","author":"Orlandi","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"25","key":"10.1016\/j.soc.2025.12.001_bib15","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.soc.2025.12.001_bib16","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.soc.2025.12.001_bib17","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.soc.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.soc.2025.12.001_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.soc.2025.12.001_bib20","doi-asserted-by":"crossref","unstructured":"Medina T., Chesney J.A., Kluger H.M., et al., Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study, J Clin Oncol, 43 (33),2025, 3565-3572, doi:10.1200\/JCO-25-00765.","DOI":"10.1200\/JCO-25-00765"},{"issue":"3","key":"10.1016\/j.soc.2025.12.001_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1173","article-title":"How T cells \u2019see' antigen","volume":"6","author":"Krogsgaard","year":"2005","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.soc.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ni1089","article-title":"Post-proteasomal antigen processing for major histocompatibility complex class I presentation","volume":"5","author":"Rock","year":"2004","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.soc.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.4049\/jimmunol.171.6.3287","article-title":"High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens","volume":"171","author":"Morgan","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.soc.2025.12.001_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/hum.2005.16.457","article-title":"Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions","volume":"16","author":"Hughes","year":"2005","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.soc.2025.12.001_bib25","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.174.7.4415","article-title":"Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines","volume":"174","author":"Zhao","year":"2005","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.soc.2025.12.001_bib26","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.4049\/jimmunol.175.9.5799","article-title":"Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR [published correction appears in J Immunol. 2006 Oct 15;177(8):5746]","volume":"175","author":"Cohen","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.soc.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/CMR.0000000000000569","article-title":"Expression of cancer\/testis antigens in cutaneous melanoma: a systematic review","volume":"29","author":"Tio","year":"2019","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.soc.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000101","article-title":"Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers","volume":"39","author":"Park","year":"2016","journal-title":"J Immunother"},{"issue":"5796","key":"10.1016\/j.soc.2025.12.001_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.soc.2025.12.001_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.soc.2025.12.001_bib31","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.soc.2025.12.001_bib32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T Cells in Synovial Saccoma","volume":"8","author":"D'Angelo","year":"2018","journal-title":"Cancer Discov"},{"issue":"10435","key":"10.1016\/j.soc.2025.12.001_bib34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.soc.2025.12.001_bib35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","article-title":"Afamitresgene autoleucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"11","key":"10.1016\/j.soc.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"30","key":"10.1016\/j.soc.2025.12.001_bib37","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a First-in-Human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.12.001_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.soc.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.soc.2025.12.001_bib40","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.soc.2025.12.001_bib41","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-18-0573","article-title":"T-cell responses to TP53 \"Hotspot\" mutations and unique neoantigens expressed by human ovarian cancers","volume":"24","author":"Deniger","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.soc.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J Clin Investig"},{"issue":"18","key":"10.1016\/j.soc.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-21-0849","article-title":"Identification and validation of T-cell receptors targeting RAS hotspot mutations in human cancers for use in cell-based immunotherapy","volume":"27","author":"Levin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib44","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","article-title":"Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors","volume":"10","author":"Kim","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.soc.2025.12.001_bib45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.humimm.2007.04.005","article-title":"High-resolution HLA alleles and haplotypes in the United States population","volume":"68","author":"Maiers","year":"2007","journal-title":"Hum Immunol"},{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","article-title":"Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers","volume":"9","author":"Parkhurst","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.soc.2025.12.001_bib47","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3389\/fimmu.2019.01392","article-title":"Determinants for neoantigen identification","volume":"10","author":"Garcia-Garijo","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.soc.2025.12.001_bib48","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.soc.2025.12.001_bib49","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2025.12.001_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000342","article-title":"Rapid identification and evaluation of neoantigen-reactive T-Cell receptors from single cells","volume":"44","author":"Paria","year":"2021","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.soc.2025.12.001_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010993","article-title":"Utilization of primary tumor samples for cancer neoantigen discovery","volume":"13","author":"Leko","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00262-025-04091-3","article-title":"Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers","volume":"74","author":"Gustafson","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"6583","key":"10.1016\/j.soc.2025.12.001_bib53","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.abl5447","article-title":"Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers","volume":"375","author":"Lowery","year":"2022","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.soc.2025.12.001_bib54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.soc.2025.12.001_bib55","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","article-title":"Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results","volume":"30","author":"Parkhurst","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.soc.2025.12.001_bib56","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"20","key":"10.1016\/j.soc.2025.12.001_bib57","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic Melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.12.001_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J Immunother"},{"issue":"12","key":"10.1016\/j.soc.2025.12.001_bib59","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z","article-title":"Clinical effects and toxicity of interleukin-2 in patients with cancer","volume":"58","author":"Lotze","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2025.12.001_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.soc.2025.12.001_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.soc.2025.12.001_bib62","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41467-022-29203-w","article-title":"A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity","volume":"13","author":"Pyke","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.soc.2025.12.001_bib63","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.soc.2025.12.001_bib64","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.soc.2025.12.001_bib65","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.celrep.2019.04.098","article-title":"The genomic and immune landscapes of lethal metastatic breast cancer","volume":"27","author":"De Mattos-Arruda","year":"2019","journal-title":"Cell Rep"},{"issue":"Suppl 6","key":"10.1016\/j.soc.2025.12.001_bib66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12920-019-0544-1","article-title":"Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes","volume":"12","author":"Castro","year":"2019","journal-title":"BMC Med Genom"},{"issue":"16","key":"10.1016\/j.soc.2025.12.001_bib67","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1158\/0008-5472.CAN-22-2220","article-title":"Tumor-derived small extracellular vesicles inhibit the efficacy of CAR T cells against solid tumors","volume":"83","author":"Zhong","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2025.12.001_bib68","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s43018-025-00949-8","article-title":"Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors","volume":"6","author":"Zhong","year":"2025","journal-title":"Nat Cancer"},{"issue":"10358","key":"10.1016\/j.soc.2025.12.001_bib69","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.soc.2025.12.001_bib70","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.soc.2025.12.001_bib71","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.soc.2025.12.001_bib72","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CJI.0b013e3181f05b91","article-title":"Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL","volume":"33","author":"Goff","year":"2010","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.soc.2025.12.001_bib73","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"6184","key":"10.1016\/j.soc.2025.12.001_bib74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.soc.2025.12.001_bib75","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are immunogenic: Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.soc.2025.12.001_bib76","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.soc.2025.12.001_bib77","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-10-0735","article-title":"Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts","volume":"70","author":"Kerkar","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2025.12.001_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1378842","article-title":"Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors","volume":"7","author":"Kunert","year":"2017","journal-title":"OncoImmunology"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:01:23Z","timestamp":1774580483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1055320725000985"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.12.001","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-Cell Receptor Engineered T-Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}